216 related articles for article (PubMed ID: 33767381)
1. Discovery of novel antagonists targeting the DNA binding domain of androgen receptor by integrated docking-based virtual screening and bioassays.
Pang JP; Shen C; Zhou WF; Wang YX; Shan LH; Chai X; Shao Y; Hu XP; Zhu F; Zhu DY; Xiao L; Xu L; Xu XH; Li D; Hou TJ
Acta Pharmacol Sin; 2022 Jan; 43(1):229-239. PubMed ID: 33767381
[TBL] [Abstract][Full Text] [Related]
2. Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor.
Li H; Ban F; Dalal K; Leblanc E; Frewin K; Ma D; Adomat H; Rennie PS; Cherkasov A
J Med Chem; 2014 Aug; 57(15):6458-67. PubMed ID: 25062331
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel androgen receptor antagonists using structure- and ligand-based methods.
Li H; Ren X; Leblanc E; Frewin K; Rennie PS; Cherkasov A
J Chem Inf Model; 2013 Jan; 53(1):123-30. PubMed ID: 23278403
[TBL] [Abstract][Full Text] [Related]
4. Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.
Dalal K; Roshan-Moniri M; Sharma A; Li H; Ban F; Hessein M; Hsing M; Singh K; LeBlanc E; Dehm S; Tomlinson Guns ES; Cherkasov A; Rennie PS
J Biol Chem; 2014 Sep; 289(38):26417-26429. PubMed ID: 25086042
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Novel Androgen Receptor Ligands by Structure-based Virtual Screening and Bioassays.
Zhou W; Duan M; Fu W; Pang J; Tang Q; Sun H; Xu L; Chang S; Li D; Hou T
Genomics Proteomics Bioinformatics; 2018 Dec; 16(6):416-427. PubMed ID: 30639122
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis and Evaluation of Novel Substituted (5-methyl-1H-pyrazol-3-yl)- 1,3,4-oxadiazole as Potent Androgen Receptor Antagonist.
Andavar S; Vaithilingam M; Selvaraj D; Kumaran AA; Devanathan K
Anticancer Agents Med Chem; 2020; 20(1):84-93. PubMed ID: 31755396
[TBL] [Abstract][Full Text] [Related]
7. Novel androgen receptor antagonist identified by structure-based virtual screening, structural optimization, and biological evaluation.
Tang Q; Fu W; Zhang M; Wang E; Shan L; Chai X; Pang J; Wang X; Xu X; Xu L; Li D; Sheng R; Hou T
Eur J Med Chem; 2020 Apr; 192():112156. PubMed ID: 32114360
[TBL] [Abstract][Full Text] [Related]
8. Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants.
Yu J; Zhou P; Hu M; Yang L; Yan G; Xu R; Deng Y; Li X; Chen Y
Eur J Med Chem; 2019 Nov; 182():111608. PubMed ID: 31437779
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Novel Anti-Resistance AR Antagonists Guided by Funnel Metadynamics Simulation.
Chen H; Zhou Y; Wang X; Chai X; Wang Z; Wang E; Xu L; Hou T; Li D; Duan M
Adv Sci (Weinh); 2024 May; 11(19):e2309261. PubMed ID: 38481034
[TBL] [Abstract][Full Text] [Related]
10. Novel Inhibitors of androgen receptor's DNA binding domain identified using an ultra-large virtual screening.
Radaeva M; Morin H; Pandey M; Ban F; Guo M; LeBlanc E; Lallous N; Cherkasov A
Mol Inform; 2023 Aug; 42(8-9):e2300026. PubMed ID: 37193651
[TBL] [Abstract][Full Text] [Related]
11. Endocrine Disruption at the Androgen Receptor: Employing Molecular Dynamics and Docking for Improved Virtual Screening and Toxicity Prediction.
Wahl J; Smieško M
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29914135
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel androgen receptor degrading agents to treat advanced prostate cancer.
Wu H; Ren J; Zhao L; Li Z; Ye W; Yang Y; Wang J; Bian J
Eur J Med Chem; 2021 May; 217():113376. PubMed ID: 33756125
[TBL] [Abstract][Full Text] [Related]
13. Development of Novel Inhibitors Targeting the D-Box of the DNA Binding Domain of Androgen Receptor.
Radaeva M; Ban F; Zhang F; LeBlanc E; Lallous N; Rennie PS; Gleave ME; Cherkasov A
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33801338
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel androgen receptor antagonists: a hybrid approach of pharmacophore-based and docking-based virtual screening.
Liu J; Liu B; Guo G; Jing Y; Zhao G
Anticancer Drugs; 2015 Aug; 26(7):747-53. PubMed ID: 25933245
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.
Fu W; Zhang M; Liao J; Tang Q; Lei Y; Gong Z; Shan L; Duan M; Chai X; Pang J; Tang C; Wang X; Xu X; Li D; Sheng R; Hou T
J Med Chem; 2021 Dec; 64(23):17221-17238. PubMed ID: 34809430
[TBL] [Abstract][Full Text] [Related]
16. Discovery of
Chai X; Sun H; Zhou W; Chen C; Shan L; Yang Y; He J; Pang J; Yang L; Wang X; Cui S; Fu Y; Xu X; Xu L; Yao X; Li D; Hou T
J Med Chem; 2022 Feb; 65(3):2507-2521. PubMed ID: 35077161
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer.
Singh KB; Ji X; Singh SV
Mol Cancer Ther; 2018 Oct; 17(10):2079-2090. PubMed ID: 30030299
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a Small-Molecule Inhibitor Targeting the Androgen Receptor N-Terminal Domain for Castration-Resistant Prostate Cancer.
Yi Q; Liu W; Seo JH; Su J; Alaoui-Jamali MA; Luo J; Lin R; Wu JH
Mol Cancer Ther; 2023 May; 22(5):570-582. PubMed ID: 37139712
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of arylpiperazine derivatives as potential anti-prostate cancer agents.
Chen H; Yu YZ; Tian XM; Wang CL; Qian YN; Deng ZA; Zhang JX; Lv DJ; Zhang HB; Shen JL; Yuan M; Zhao SC
Bioorg Med Chem; 2019 Jan; 27(1):133-143. PubMed ID: 30482547
[TBL] [Abstract][Full Text] [Related]
20. The discovery of novel human androgen receptor antagonist chemotypes using a combined pharmacophore screening procedure.
Voet A; Helsen C; Zhang KY; Claessens F
ChemMedChem; 2013 Apr; 8(4):644-51. PubMed ID: 23436650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
